EUVIMEDSkopri EUVIMED
Multizentrische Studie

Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma

Rong Ding, Jin-Feng Bai iD, Zhi-Cheng Jin iD, Yu-Dong Xiao, Jian-Jian Chen, Xiao-Li Zhu, Yu-Jing Xin iD, Jin-Zhang Chen, Jun Tie, Kang-Shun Zhu, Lan Zhang, Hai-Bin Shi iD and 17 more

Alimentary Pharmacology & Therapeutics · 2026-06 · 63 (12) · 1617-1625

DOI: 10.1111/apt.70612 ↗

At a glance

Multizentrische Studie in Alimentary Pharmacology & Therapeutics, published online on 2026-03-31. Written by Rong Ding and 28 co-authors. Institution: Department of Minimally Invasive Intervention, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University…. Major MEDLINE topics: Carcinoma, Hepatocellular, Liver Neoplasms, Pyridines, Antibodies, Monoclonal, Humanized. Cited 3 times so far (Crossref); 26 references. Funded by: National Natural Science Foundation of China, Yunnan Science and Technology Talent and Platform Program, Jiangsu Provincial Basic Research Program Natural Science Foundation-Frontier Leading Technology Basic Research Project.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Background

This real‐world study aimed to evaluate and compare the efficacy and safety of two treatment strategies for advanced hepatocellular carcinoma (HCC): transarterial chemoembolisation (TACE) combined with camrelizumab and apatinib versus camrelizumab and apatinib alone.

Methods

In this nationwide, multi‐centre retrospective cohort study, data were collected on patients with advanced HCC who received either TACE combined with camrelizumab and apatinib (T‐C‐A) or camrelizumab and apatinib alone (C‐A) between January 2018 and December 2022. To reduce potential bias, stabilised inverse probability of treatment weighting (sIPTW) was applied. The primary outcome was overall survival (OS), while secondary outcomes included progression‐free survival (PFS), objective response rate (ORR) based on RECIST v1.1 criteria, and safety.

Results

A total of 252 HCC patients were included (T‐C‐A group, n = 183; C‐A group, n = 69). Among them, 210 were males and 42 were females, with a median age of 54 years. After sIPTW, the median OS was significantly longer in the T‐C‐A group compared to the C‐A group (24.2 months [95% CI: 21.4–33.4] vs. 15.2 months [95% CI: 9.8–21.0]; p < 0.001). The T‐C‐A group also demonstrated a significantly improved median PFS of 10.1 months [95% CI: 8.8–12.2], compared to 4.9 months [95% CI: 4.0–12.5] in the C‐A group ( p < 0.001). Further, the ORR was higher in the T‐C‐A group. Grade 3/4 adverse events were reported in 12.0% of patients in the T‐C‐A group and 14.5% in the C‐A group.

Conclusion

The combination of TACE with camrelizumab and apatinib suggests potential survival advantages for patients with advanced HCC while maintaining an acceptable safety profile.(Study series number CHANCE 2311).

Subjects

MeSH terms (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPyridinesAntibodies, Monoclonal, HumanizedChemoembolization, TherapeuticAntineoplastic AgentsHumansFemaleMaleRetrospective StudiesMiddle AgedTreatment OutcomeAgedAdultProgression-Free SurvivalCombined Modality Therapy

Author keywords

apatinibcamrelizumabhepatocellular carcinomaprognosistransarterial chemoembolisation

Substances

apatinibPyridinescamrelizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents

Authors and institutions

  • Department of Minimally Invasive Intervention, The Third Affiliated Hospital of Kunming Medical University, Yunnan Cancer Hospital, Peking University Cancer Hospital Yunnan, Kunming, China.
  • Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
  • Basic Medicine Research and Innovation Center of Ministry of Education, Zhongda Hospital, Southeast University, Nanjing, China.
  • Department of Radiology, The Second Xiangya Hospital of Central South University, Hunan, China.
  • Department of Interventional Radiology, Sichuan Cancer Hospital and Institute, Chengdu, China.
  • Department of Interventional Radiology, the First Affiliated Hospital of Soochow University, Soochow University, Suzhou, China.

ORCID profiles: Jin-Feng Bai, Zhi-Cheng Jin, Yu-Jing Xin, Hai-Bin Shi, Fanpu Ji, Jian-Song Ji, Hai-Dong Zhu, Zheng-Gang Ren, Gao-Jun Teng

Funding

  • National Natural Science Foundation of China
  • Yunnan Science and Technology Talent and Platform Program
  • Jiangsu Provincial Basic Research Program Natural Science Foundation-Frontier Leading Technology Basic Research Project
  • Jiangsu Provincial Collaborative Innovation in Medical-Education-Research-Industry Integration
  • China Postdoctoral Science Foundation
  • Postdoctoral Fellowship Program of CPSF
  • Natural Science Foundation of Jiangsu Province
  • National Key Research and Development Program of China

Cite

APA

Ding, R., Bai, J. F., Jin, Z. C., Xiao, Y. D., Chen, J. J., Zhu, X. L., Xin, Y. J., Chen, J. Z., Tie, J., Zhu, K. S., Zhang, L., Shi, H. B., Liu, R. B., Xu, A. B., Ji, F., Huang, M. S., Ji, J. S., Yuan, C. W., Yang, W. Z., …, & Teng, G. J. (2026). Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics, 63(12), 1617-1625. https://doi.org/10.1111/apt.70612

Vancouver

Ding R, Bai JF, Jin ZC, Xiao YD, Chen JJ, Zhu XL, et al. Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics. 2026;63(12):1617-1625. doi:10.1111/apt.70612

BibTeX
@article{Ding2026,
  author = {Ding, Rong and Bai, Jin-Feng and Jin, Zhi-Cheng and Xiao, Yu-Dong and Chen, Jian-Jian and Zhu, Xiao-Li and Xin, Yu-Jing and Chen, Jin-Zhang and Tie, Jun and Zhu, Kang-Shun and Zhang, Lan and Shi, Hai-Bin and Liu, Rui-Bao and Xu, Ai-Bing and Ji, Fanpu and Huang, Ming-Sheng and Ji, Jian-Song and Yuan, Chun-Wang and Yang, Wei-Zhu and Xu, Guo-Hui and Tu, Qiang and Jiang, Hua and Shao, Hai-Bo and Shi, Bao-Qi and Huang, Ming and Zhong, Bin-Yan and Zhu, Hai-Dong and Ren, Zheng-Gang and Teng, Gao-Jun},
  title = {Camrelizumab and Apatinib With or Without Transarterial Chemoembolisation as First‐Line Treatment for Advanced Hepatocellular Carcinoma},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  volume = {63},
  number = {12},
  pages = {1617--1625},
  doi = {10.1111/apt.70612}
}
Start for free →